The incredible growth story of Valeant Pharmaceuticals Intl Inc (TSX:VRX)(NYSE:VRX) does not appear to be ending anytime soon. Investors and analysts alike were impressed by the myriad of deals the company did to acquire other companies over the past years, each acquisition more impressive than the previous one, sending the stock higher.

Given the current economy as well as the pace at which Valeant has grown, it begs the question of how long can this growth continue, and does this still make Valeant a good option for your portfolio?

To answer the question, let’s first start by examining how the company is doing.

How is the company doing?

Valeant is currently trading at $301.25. Yes, this is an expensive stock to own, but with good reason. While the overall market has lost its steam and has dropped some 7%, Valeant continues moving upward, and is up nearly 5% in the past three months.

Outside of the current quarter of economic slowness, the company is up an impressive 85% year-to-date. Extend this out to an entire year, and the company is up 142%. Long-term investors will take note of the best-kept secret about Valeant—the five-year number is an awe-inspiring 1,166%

This incredible growth has seen Valeant pass the Royal Bank of Canada to become the most valuable company in Canada. What’s more impressive is that Valeant continues to grow with no sign of slowing down.

Valeant isn’t done expanding yet

Valeant is renowned for the ability to acquire and integrate other companies into its existing and ever-growing distribution network. Here are two of the more recent acquisitions—and in case you are wondering, there have been seven so far in 2015 alone:

Synergetics is an ophthalmic surgical device manufacturer. The company was purchased at a 48% premium over the company’s closing price in a deal that is reported to be worth $166 million.

The deal is expected to be completed during the fourth quarter of the year, and is expected to boost the expanding portfolio of eye products that Valeant offers.

Sprout Pharmaceuticals is the company responsible for manufacturing the drug Addyi— otherwise known as the female Viagra. The FDA approved the drug for sale only a few weeks ago, and Valeant appeared within two days and snatched up the company for a reported $1 billion.

Valeant CEO Mike Pearson noted that the drug could earn revenue in the hundreds of millions, if not billions for the company. The drug is slated to begin sale in October.

The significance of this deal is off the charts. It represents the company’s first foray into women’s health, and the ludicrous potential this deal brings in terms of revenue for years to come.

In my opinion, Valeant continues to be a great option for the investor seeking growth.

The 1 stock you want to own for 2015

Does your portfolio have rock-solid blue chips at its core? If it does... GREAT! If not, you might want to reconsider your strategy.

Either way, we think you should take a look at what our analysts have identified as one TOP stock for 2015 and beyond -- a stock with a tollbooth-like business; a solid management team; and a reliable, consistent, and rising dividend -- and you can download the name, ticker symbol, and price guidance absolutely FREE.

Simply click here to receive your Special FREE Report, "1 Top Stock for 2015 -- and Beyond."


Let’s not beat around the bush – energy companies performed miserably in 2015. Yet, even though the carnage was widespread, not all energy-related businesses were equally affected.

We've identified an energy company we think offers one of the best growth opportunities around. While this company is largely tied to the production of natural gas, it doesn't actually produce the gas. Instead, it provides the equipment required to get natural gas from the ground to the end user. With diversified operations around the globe, we think it's a rare find in the industry.

We like it so much, we’ve named it as 1 Top Stock for 2016 and Beyond. To find out why, simply enter your email address below to claim your FREE copy of this brand new report, "1 Top Stock for 2016 and Beyond"!

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.